Justin M. Lopchuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justin M. Lopchuk has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Ernst Schönbrunn
H. Lee Moffitt Cancer Center and Research Institute
13 shared publications - Bin Fang
Moffitt Cancer Center
12 shared publications - Zachary P. Shultz
Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
12 shared publications - Jiandong Chen
Moffitt Cancer Center 1 Department of Molecular Oncology Tampa, Florida
11 shared publications - Lihong Chen
Moffitt Cancer Center 1 Department of Molecular Oncology Tampa, Florida
11 shared publications - Marianna Sansone
Molecular Oncology Department, Moffitt Cancer Center, Tampa, Florida
11 shared publications
Latest Publications
- Open Access
- 15 August 2026
- Published by Georg Thieme Verlag KG in Synthesis
Synthesis of the A/B Ring System of Withaferin A-type Withanolides
Withanolides are C28 steroidal lactone plant-based natural products with diverse pharmacologic activities, yet their synthesis remains challenging owing to the highly oxidized A/B ring system. Herein, we report a concise, protecting group-free route to the 1-oxo-2-ene-4β-hydroxy-5β,6β-epoxy A/B ring motif, a key pharmacophore feature of many withanolides. Starting from commercially available stigmasterol, the target framework is assembled in nine steps, featuring a Wharton rearrangement and diastereoselective epoxidation directed by an axial hydroxyl group. This strategy offers an orthogonal approach to existing routes and provides efficient access to this synthetically challenging core, thereby facilitating structure–activity relationship studies and biological evaluations of withanolide natural products.
- 15 August 2026
- Published by Georg Thieme Verlag KG in Synthesis
Open AccessSynthesis of the A/B Ring System of Withaferin A-type Withanolides
Withanolides are C28 steroidal lactone plant-based natural products with diverse pharmacologic activities, yet their synthesis remains challenging owing to the highly oxidized A/B ring system. Herein, we report a concise, protecting group-free route to the 1-oxo-2-ene-4β-hydroxy-5β,6β-epoxy A/B ring motif, a key pharmacophore feature of many withanolides. Starting from commercially available stigmasterol, the target framework is assembled in nine steps, featuring a Wharton rearrangement and diastereoselective epoxidation directed by an axial hydroxyl group. This strategy offers an orthogonal approach to existing routes and provides efficient access to this synthetically challenging core, thereby facilitating structure–activity relationship studies and biological evaluations of withanolide natural products.
- 23 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6809) , 408-416
Late-stage functionalization with strain-release warheads enables tunable covalent inhibition
Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.
- 23 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6809) , 408-416
Late-stage functionalization with strain-release warheads enables tunable covalent inhibition
Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.
- 5 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (24) , 7655-7660
Mild Transsulfinamidation Enables Rapid Access to Sulfinamides, Sulfonamides, and Sulfonimidamides
A mild and late-stage compatible transsulfinamidation of sulfinamides with diverse amine salts and (hetero)aryl amines is reported. Readily available amine salts promote the reaction under Brønsted acidic conditions without metal catalysis or preactivation, exhibiting broad compatibility with functional groups and complex pharmaceutical scaffolds. The resulting N-substituted sulfinamides represent versatile intermediates for late-stage diversification, enabling efficient synthesis of sulfonamides and sulfonimidamides and providing streamlined access to structurally diverse S(VI) motifs from readily available amines.
- 5 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (24) , 7655-7660
Mild Transsulfinamidation Enables Rapid Access to Sulfinamides, Sulfonamides, and Sulfonimidamides
A mild and late-stage compatible transsulfinamidation of sulfinamides with diverse amine salts and (hetero)aryl amines is reported. Readily available amine salts promote the reaction under Brønsted acidic conditions without metal catalysis or preactivation, exhibiting broad compatibility with functional groups and complex pharmaceutical scaffolds. The resulting N-substituted sulfinamides represent versatile intermediates for late-stage diversification, enabling efficient synthesis of sulfonamides and sulfonimidamides and providing streamlined access to structurally diverse S(VI) motifs from readily available amines.
- 3 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (23) , 7315-7320
Unactivated Photoredox C–H Amination with Diazirines: Access to Acyldiaziridines
A metal-free, photoinduced amination of unactivated C-H bonds from abundant, simple alkanes with diazirines is reported. The transformation provides diversifiable diaziridine products (40 examples) in up to 95% yields. The conditions are suitable for four different classes of C-H bonds, including aldehydes, which results in the formation of previously unavailable acyldiaziridines. This class of molecules is shown to consist of versatile precursors that are easily converted into amides, hydrazides, acyl hydrazones, and heterocycles.
- 3 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (23) , 7315-7320
Unactivated Photoredox C–H Amination with Diazirines: Access to Acyldiaziridines
A metal-free, photoinduced amination of unactivated C-H bonds from abundant, simple alkanes with diazirines is reported. The transformation provides diversifiable diaziridine products (40 examples) in up to 95% yields. The conditions are suitable for four different classes of C-H bonds, including aldehydes, which results in the formation of previously unavailable acyldiaziridines. This class of molecules is shown to consist of versatile precursors that are easily converted into amides, hydrazides, acyl hydrazones, and heterocycles.
- Open Access
- 26 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Unactivated Photoredox C–H Amination with Diazirines: Access to Acyldiaziridines.
A metal-free, photoinduced amination of unactivated C–H bonds from abundant, simple alkanes with diazirines is reported. The transformation provides diversifiable diaziridine products (39 examples) in up to 95% yield. The conditions are suitable for four different classes of C–H bonds, including aldehydes, which results in the formation of previously unavailable acyldiaziridines. This class of molecules is shown to be a versatile precursor that is easily converted to amides, hydrazides, acyl hydrazones, and heterocycles.
- 26 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessUnactivated Photoredox C–H Amination with Diazirines: Access to Acyldiaziridines.
A metal-free, photoinduced amination of unactivated C–H bonds from abundant, simple alkanes with diazirines is reported. The transformation provides diversifiable diaziridine products (39 examples) in up to 95% yield. The conditions are suitable for four different classes of C–H bonds, including aldehydes, which results in the formation of previously unavailable acyldiaziridines. This class of molecules is shown to be a versatile precursor that is easily converted to amides, hydrazides, acyl hydrazones, and heterocycles.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Synthetic chemistry procedures
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Synthetic chemistry procedures
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 2. RNA-seq analysis of differentially regulated genes after ZS3-046 treatment.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 2. RNA-seq analysis of differentially regulated genes after ZS3-046 treatment.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 5. TAF1 depletion by PROTAC activates p53.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 5. TAF1 depletion by PROTAC activates p53.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 3. Effects of TAF1 PROTAC on cell cycle profile.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 3. Effects of TAF1 PROTAC on cell cycle profile.